At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.Listen to the podcast to hear Dr. Goetz explain:
how Verzenio works
the aims of MONARCH 3 study
the difference between progression-free and overall survival and why each is important
Verzenio side effects
what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More